Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

394 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anticancer innovative therapy congress: Highlights from the 10th anniversary edition.
De Santis F, Fucà G, Schadendorf D, Mantovani A, Magnani L, Lisanti M, Pettitt S, Bellone M, Del Sal G, Minucci S, Eggermont A, Bruzzi P, Bicciato S, Conte P, Noberini R, Hiscott J, De Braud F, Del Vecchio M, Di Nicola M. De Santis F, et al. Among authors: bruzzi p. Cytokine Growth Factor Rev. 2021 Jun;59:1-8. doi: 10.1016/j.cytogfr.2021.02.001. Epub 2021 Feb 14. Cytokine Growth Factor Rev. 2021. PMID: 33610464 Review.
Malignant melanoma.
de Braud F, Khayat D, Kroon BB, Valdagni R, Bruzzi P, Cascinelli N. de Braud F, et al. Among authors: bruzzi p. Crit Rev Oncol Hematol. 2003 Jul;47(1):35-63. doi: 10.1016/s1040-8428(02)00077-x. Crit Rev Oncol Hematol. 2003. PMID: 12853098 Review.
Bladder cancer.
de Braud F, Maffezzini M, Vitale V, Bruzzi P, Gatta G, Hendry WF, Sternberg CN. de Braud F, et al. Among authors: bruzzi p. Crit Rev Oncol Hematol. 2002 Jan;41(1):89-106. doi: 10.1016/s1040-8428(01)00128-7. Crit Rev Oncol Hematol. 2002. PMID: 11796234 Review.
The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.
Ascierto PA, Bruzzi P, Eggermont A, Hamid O, Tawbi HA, van Akkooi A, Testori A, Caracò C, Puzanov I, Perrone F. Ascierto PA, et al. Among authors: bruzzi p. J Transl Med. 2019 May 10;17(1):148. doi: 10.1186/s12967-019-1892-5. J Transl Med. 2019. PMID: 31077205 Free PMC article.
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
Guarneri V, Frassoldati A, Bruzzi P, D'Amico R, Belfiglio M, Molino A, Bertetto O, Cascinu S, Cognetti F, Di Leo A, Pronzato P, Crinó L, Agostara B, Conte P. Guarneri V, et al. Among authors: bruzzi p. Clin Breast Cancer. 2008 Oct;8(5):453-6. doi: 10.3816/CBC.2008.n.056. Clin Breast Cancer. 2008. PMID: 18952561 Clinical Trial.
394 results